YFYu Fan

Yu Fan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu Fan has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Dandan Gong

    Cancer Institute, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China

    19 shared publications
  • Changfeng Man

    Cancer Institute, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China

    12 shared publications
  • Juan Xu

    Department of Oncology, Ganyu District People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China

    11 shared publications
  • Dandan Gong

    Cancer Institute, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China

    9 shared publications
  • Yimeng Sun

    Institute of Molecular Biology & Translational Medicine, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, Jiangsu, 212002 China

    9 shared publications
  • Yue Qiu

    Cancer Institute, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China

    8 shared publications

Latest Publications

  • Systemic inflammatory response syndrome and adverse outcomes in acute intracerebral hemorrhage: a meta-analysis

    by Lang Bu, Honghua Dai, Hao Du, Yu Fan

    Objective Systemic inflammatory response syndrome (SIRS) frequently complicates acute intracerebral hemorrhage (ICH) and may affect patient prognosis. However, the prognostic value of SIRS in patients with acute ICH remains controversial. This meta-analysis aimed to assess the prognostic significance of SIRS in this patient population. Methods We systematically searched PubMed, Embase, and Web of Science to identify studies investigating the associations between SIRS and adverse outcomes—namely mortality, poor functional outcome (PFO), and hematoma expansion—in patients with acute ICH. Pooled adjusted odds ratios (OR) with 95% confidence intervals (CI) were synthesized using a random-effects model. Results Nine studies enrolling a total of 6,976 patients with acute ICH were included. Meta-analyses revealed that patients with acute ICH complicated by SIRS exhibited a substantially higher risk of short-term mortality (OR 2.43; 95% CI 1.48–3.99) relative to patients without SIRS. SIRS was also associated with increased risks of PFO at 3 months (OR 1.47; 95% CI 1.15–1.88) and at 12 months (OR 1.76; 95% CI 1.16–2.68), whereas no significant association was observed for PFO at hospital discharge (OR 2.41; 95% CI 0.69–8.44). Moreover, SIRS was associated with a significantly higher risk of hematoma expansion (OR 2.76; 95% CI 1.68–4.54). Conclusions The development of SIRS is associated with increased risks of short-term mortality, PFO, and hematoma expansion in acute ICH patients. However, these findings should be considered exploratory due to the limited number of prior studies. Large prospective investigations are needed to validate these results and clarify the potential clinical utility of SIRS assessment.

  • Association between Weight Loss and Survival Outcomes in Patients with Esophageal Cancer: A Meta-Analysis

    by Mei Jiang, Yueshi Zhang, Yu Fan

    Esophageal cancer is one of the most aggressive malignancies worldwide (1). This disease comprises several pathological subtypes, with the two primary types being esophageal squamous cell carcinoma...

  • Association Between Atherogenic Index of Plasma and Cardiovascular Events or Mortality in the General Population: A Meta-Analysis of Longitudinal Studies

    by Jiamei Cai, Yueshi Zhang, Yu Fan

    Introduction: The balance between plasma triglycerides and high-density lipoprotein cholesterol is evaluated using the Atherogenic Index of Plasma (AIP). We aimed to synthesize evidence from meta-analyses on the association between the AIP and major adverse cardiovascular events (MACEs) or mortality in the general population. Methods: Embase, Web of Science, and PubMed were searched for publications up to January 28, 2025. Cohort studies reporting the association between AIP and the risks of MACEs and mortality in the general population were included. Results: Fifteen studies (16 articles), encompassing a total of 901,640 individuals, met the inclusion criteria. Comparing individuals with the highest AIP to those with the lowest, the pooled adjusted HR indicated significantly elevated risks MACEs (hazard ratios [HR] 1.33; 95confidence intervals [CI] 1.22-1.46), coronary heart disease (CHD) (HR 1.72; 95% CI 1.51-1.95), stroke (HR 1.49; 95% CI 1.03-2.15), all-cause mortality (HR 1.24; 95% CI 1.10-1.39), and cardiovascular mortality (HR 1.17; 95% CI 1.05-1.31). However, the observed association between elevated AIP and stroke was not confirmed in the sensitivity analysis. Discussion: These findings suggest that measuring blood AIP level may help identify high-risk individuals for death and cardiovascular events in the general population. However, the results of subgroup analyses should be interpreted cautiously due to the limited number of studies available within each subgroup. Conclusion: Elevated AIP is an independent predictor of MACEs, CHD, cardiovascular mortality, and all-cause mortality in the general population. Further prospective studies are essential to validate these findings and to optimize the clinical application of AIP.


  • Open Access

    Prostate-specific antigen velocity as a predictor of survival outcomes in patients with prostate cancer: a meta-analysis

    by Feilun Cui, Yueshi Zhang, Ziyan Liu, Yongjing Zhou, Changfeng Man, Yu Fan

    Background: Prostate-specific antigen velocity (PSAV) has emerged as a promising biomarker for predicting survival outcomes in prostate cancer patients. Objectives: To assess the association between PSAV and both all-cause mortality and prostate cancer-specific mortality (PCSM) in men diagnosed with prostate cancer by conducting a meta-analysis. Methods: A comprehensive search of electronic medical databases, including PubMed, Web of Science, and Embase, was conducted to identify relevant studies published up to March 1, 2025. Studies reporting adjusted hazard ratios (HR) with 95% confidence intervals (CI) for survival outcomes in prostate cancer patients, based on categorical analyses of PSAV, were included. Pooled HRs with 95% CI was calculated using random-effects models to account for clinical heterogeneity across studies. Result: Eleven studies involving 3,713 prostate cancer patients were identified and analyzed. The meta-analysis revealed that elevated PSAV was associated with a higher risk of both all-cause mortality (HR 1.96; 95% CI 1.33–2.88) and PCSM (HR 5.38; 95% CI 2.76–10.51). In stratified analyses, the pooled HR for all-cause mortality was 1.91 (95% CI 1.43–2.55) among patients with localized prostate cancer, compared to 1.26 (95% CI 0.41–3.84) in those with metastatic disease. Conclusions: Elevated PSAV is a significant predictor of all-cause mortality and PCSM in prostate cancer patients. Measuring PSAV has the potential to improve the prediction of survival outcomes in this population. However, further research is needed to standardize PSAV measurement and validate its predictive value across diverse patient groups. Systematic review registration.

  • Open Access

    Association between weight loss and survival outcomes in patients with colorectal cancer: a meta-analysis

    by Guofang Wang, Ziyan Liu, Dandan Gong, Changfeng Man, Yu Fan

    Background Weight reduction is a common clinical feature observed in patients with colorectal cancer and often reflects underlying tumor burden or nutritional status. This meta-analysis aims to systematically synthesize existing evidence on the relationship between weight loss and survival outcomes in patients with colorectal cancer. Methods An exhaustive literature search was conducted in PubMed, Embase, and Web of Science, covering all records from the inception of each database through May 15, 2025. Inclusion criteria focused on studies reporting quantitative associations between weight loss and overall survival, progression-free survival, and colorectal cancer–specific mortality in patients with colorectal cancer. For the meta-analytic synthesis, adjusted hazard ratios (HR) with 95% confidence intervals (CI) were pooled using a random-effects model. Results Thirteen eligible studies involving 17,606 colorectal cancer patients were identified. Pooled estimates derived from random-effects modeling indicated that weight loss was significantly associated with shorter overall survival (HR 2.02; 95% CI 1.67–2.44) and progression-free survival (HR 1.34; 95% CI 1.14–1.58). Additionally, weight loss was linked to an increased risk of colorectal cancer–specific mortality (HR 3.27; 95% CI 1.75–6.12). Subgroup analyses revealed notably reduced overall survival among patients aged over 60 years (HR 2.94; 95% CI 2.45–3.53) and those experiencing weight loss of 10% or more (HR 3.19; 95% CI 2.58–3.93), compared to their counterparts. Conclusions Weight loss is a significant and independent prognostic indicator of reduced survival in patients with colorectal cancer. Further rigorous prospective studies are needed to confirm these findings and to investigate the potential underlying biological mechanisms.


  • Association between overweight and obesity determined by body mass index and overall survival in patients with metastatic prostate cancer: a meta-analysis

    by Feilun Cui, Yueshi Zhang, Ziyan Liu, Changfeng Man, Dandan Gong, Yongjing Zhou, Yu Fan

    Studies on the association between obesity and mortality in patients with prostate cancer have yielded inconclusive findings. This meta-analysis aimed to evaluate the association between overweight/obesity determined by body mass index (BMI) and overall survival (OS) in patients with metastatic prostate cancer (mPC). A systematic search was conducted in the PubMed, Web of Science, and Embase databases until February 2025. Studies that evaluated the association between overweight/obesity and OS in patients with mPC were considered. Fifteen studies reported in 13 articles, including 18,280 patients, were identified. The overall pooled adjusted HR for OS was 0.79 (95% CI 0.73-0.85) for patients with overweight/obesity versus those with normal weight. The pooled adjusted HR for OS was 0.81(95%CI 0.75-0.87) for overweight and 0.78 (95%CI 0.67-0.90) for obesity. Furthermore, the association of overweight (HR 0.78; 95% CI 0.71-0.85) and obesity (HR 0.73; 95% CI 0.59-0.90) with OS was more pronounced in patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, each 1-unit increase in BMI was associated with a 4% (95% CI 1.0-8.0%) improvement in OS. Patients with mPC who have overweight or obesity, as defined by BMI, are associated with improved overall survival, particularly in those with mCRPC.


  • Open Access

    Weight gain or loss after diagnosis and survival outcomes in prostate cancer: a meta-analysis

    by Feilun Cui, Yueshi Zhang, Xuan Tang, Dandan Gong, Changfeng Man, Yong Shan, Yongjing Zhou, Yu Fan

    The relationship between weight changes and survival outcomes in patients with prostate cancer remains inconclusive. This meta-analysis aims to investigate the association between post-diagnosis weight changes and survival outcomes in patients with prostate cancer. We systematically searched for articles indexed in the PubMed, Web of Science, and Embase databases until March 22, 2025. Longitudinal observational studies that examined the association between post-diagnosis weight change and prostate cancer-specific mortality (PCSM) or all-cause mortality among patients with prostate cancer were eligible for inclusion in this analysis. Weight gain and weight loss were defined as either a percentage change from baseline body weight at diagnosis or treatment start, or as an absolute change in kilograms over a specified period. Despite variations in the measured statistical heterogeneity, we employed a random-effects model for all meta-analyses to account for inherent differences in the definitions of weight change. Six studies involving 12,269 patients were included in the meta-analysis. When compared to a reference stable weight, post-diagnosis weight gain was associated with an increased risk of all-cause mortality (hazard ratio [HR] 1.23; 95% confidence interval [CI] 1.07–1.42) and PCSM (HR 1.64; 95% CI 1.30–2.07). Conversely, weight loss was linked to an increased risk of all-cause mortality (HR 1.54; 95% CI 1.20–1.97), while no significant association was found between weight loss and PCSM (HR 1.30; 95% CI 0.76–2.22). Begg’s and Egger’s tests indicated no evidence of publication bias. Subgroup analyses revealed that both weight loss (HR 1.38; 95% CI 1.07–1.79) and weight gain (HR 1.25; 95% CI 1.08–1.46) were significantly associated with all-cause mortality when the analysis was restricted to patients with non-metastatic or localized prostate cancer. Post-diagnosis weight gain is significantly associated with both all-cause mortality and PCSM in patients with prostate cancer, particularly in those with non-metastatic or localized disease. In contrast, weight loss is primarily linked to an increased risk of all-cause mortality but not to PCSM. However, the observational nature of our data limits our ability to draw definitive conclusions regarding causality. The online version contains supplementary material available at 10.1186/s12885-025-14704-w.

  • Prefrailty prevalence and all‐cause mortality risk in older adults from the general population: A meta‐analysis of prospective cohort studies

    by Li Yu, Xuan Tang, Dandan Gong, Changfeng Man, Yu Fan

    Aim: Prefrailty represents an intermediate stage between robust health and frailty. This meta‐analysis aimed to estimate the global prevalence of prefrailty and evaluate its association with all‐cause mortality in older adults from the general population.Methods: Two independent reviewers systematically searched PubMed, Web of Science, and Embase for relevant studies published through to December 10, 2024. Eligible studies reported either prefrailty prevalence or all‐cause mortality risk in older adults from the general population aged 65 years and older.Results: The analysis included 26 studies (25 articles; N = 222 473). The included studies utilized the Fried frailty phenotype and frailty index to define prefrailty. The pooled prefrailty prevalence was 45% (95% confidence interval [CI] 42–48%), with similar rates across assessment methods. Prefrailty significantly increased all‐cause mortality risk (hazard ratio [HR] 1.38; 95% CI 1.32–1.45). Sex‐specific analyses showed a marginally higher risk in men (HR 1.39; 95% CI 1.30–1.49) than in women (HR 1.33; 95% CI 1.25–1.41). Mortality associations were stronger when prefrailty was defined by the frailty index (HR 1.47; 95% CI 1.35–1.61) than by phenotype (HR 1.37; 95% CI 1.32–1.42).Conclusions: Nearly half of older adults exhibit prefrailty, which confers a 38% increased mortality risk in older adults from the general population. These findings underscore the need for early identification and intervention in this high‐risk subgroup. Geriatr Gerontol Int 2025; 25: 1167–1177.


  • Open Access

    Adjuvant treatment with Wu-Zi-Yan-Zong formula for abnormal sperm parameters associated with male infertility: a meta-analysis of randomized controlled trials

    by Feilun Cui, Yueshi Zhang, Yu Fan

    Background: Wu-Zi-Yan-Zong (WZYZ) formula is a traditional Chinese botanical drug that has been used to treat male infertility. This meta-analysis aims to evaluate its effectiveness of the WZYZ formula as an adjuvant therapy for treating abnormal sperm parameters associated with male infertility.Methods: A comprehensive literature search was conducted using PubMed, Embase, Cochrane Library, Web of Science, SinoMed, Wanfang, and CNKI databases until December 12, 2024 to identify randomized controlled trials (RCTs) that assessed the effectiveness of the WZYZ formula as an adjuvant therapy for treating abnormal sperm parameters associated in men with infertility. For dichotomous data, the pooled results were summarized as risk ratio (RR) with 95% confidence intervals (CI), while continuous data were expressed as pooled weighted mean difference (WMD) with 95% CI.Results: A total of 11 RCTs involving 951 men were identified. The pooled results showed that the WZYZ formula, when combined with control treatment, significantly improved the pregnancy rate of female partners (RR 1.68; 95% CI 1.34–2.11), semen volume (WMD 0.58 mL; 95% CI 0.28–0.89), sperm concentration (WMD 6.87 × 106/mL; 95%CI 4.24–9.51), total sperm motility (WMD 15.55%; 95% CI 10.38–20.72), forward grade (a) sperm motility (WMD 5.44%; 95% CI 1.86–9.01), forward grade (a + b) sperm motility (WMD 7.14%; 95% CI 4.04–10.23), abnormal sperm morphology (WMD −10.38%; 95% CI −15.72 to −5.03), and activity of the acrosome enzyme (WMD 8.02 × 106 μIU; 95% CI 3.58–12.46.Conclusion: Adjuvant treatment with WZYZ formula significantly improves the pregnancy rate of female partners by improving several semen parameters in infertile men with abnormal sperm parameters. However, further well-designed RCTs with larger sample sizes are necessary to definitively determine the efficacy and safety of the WZYZ formula in treating abnormal sperm parameters associated with male infertility.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024629510.


  • Open Access

    Association between type 2 diabetes and gastric cancer in Europeans and East Asians based on two sample Mendelian randomization

    by Xiaoyan Wang, Luyu Zhu, Ziyan Liu, Changfeng Man, Zhenjun Gao, Dandan Gong, Yu Fan

    Background There are conflicting results and potential methodological flaws of previous observational studies on the association between T2DM and the risk of gastric cancer.This two-sample Mendelian randomization (MR) study aimed to investigate the causal association between type 2 diabetes mellitus (T2DM) and gastric cancer in different ethnic populations. Methods Exposure variables were obtained from genome-wide association studies (GWAS) of T2DM in European population (finn-b-E4_DM2; 32,469) and East Asian population (ebi-a-GCST90018706; n = 45,383). Concomitantly, we utilized summary-level genetic data for gastric cancer in Europeans population (ebi-a-GCST90018849; n = 1029) and East Asians population (ebi-a-GCST90018629; n = 7,921) as the outcome measure. Causal associations between T2DM and gastric cancer in the same ethnic groups were primarily determined using the inverse-variance weighted (IVW) method. Results A total of 62 and 106 single nucleotide polymorphisms associated with T2DM were selected for in Europeans and East Asians, respectively. The IVW analysis indicated that there was a significant inverse association between T2DM and gastric cancer in Europeans (odds ratio [OR] 0.917; 95% confidence interval [CI] 0.855–0.984) and East Asians (OR 0.881; 95% CI 0.845–0.918). The weighted median and Weighted mode regression models produced similar results. MR-Egger regression analysis suggested the absence of horizontal pleiotropy. The leave-out sensitivity analysis demonstrated that the results were stable. Conclusion This MR study revealed that T2DM may be associated with a reduced risk of gastric cancer in European and East Asian population.